Search
PF-00489791
go.drugbank.com/drugs/DB11736InvestigationalPF-00489791 has been used in trials studying the treatment of Hypertension, Raynaud's Disease, Diabetic Nephropathies, Hypertension, Pulmonary, and Peripheral Vascular Disease.
Zelavespib
go.drugbank.com/drugs/DB12638InvestigationalZelavespib (PU-H71) has been used in trials studying the treatment of LYMPHOMA, Solid Tumors, Metastatic Solid Tumor, and Myeloproliferative Neoplasms (MPN).
PF-03882845
go.drugbank.com/drugs/DB11814InvestigationalPF-03882845 has been used in trials studying the basic science of Diabetes Mellitus, Type 2 and Type 2 Diabetic Nephropathy.
Tomivosertib
go.drugbank.com/drugs/DB15219InvestigationalTomivosertib is under investigation in clinical trial NCT03318562 (A PD Study of Oral eFT508 in Subjects With Advanced TNBC and HCC).
Erfonrilimab
go.drugbank.com/drugs/DB17446InvestigationalErfonrilimab is a bispecific monoclonal antibody directed against both the programmed cell death-1 ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA4).
Gremubamab
go.drugbank.com/drugs/DB15014InvestigationalGremubamab is under investigation in clinical trial NCT02255760 (Phase 1 Randomized Double-blind Placebo Controlled Study to Evaluate Safety and PK of MEDI3902 in Healthy Adults).
Ponezumab
go.drugbank.com/drugs/DB15135InvestigationalPonezumab is under investigation in clinical trial NCT00607308 (A Phase I, Single Dose Study Of PF-04360365 In Japanese Patients With Mild To Moderate Alzheimer's Disease).
Synonyms: PF-04360365Ranibizumab
go.drugbank.com/drugs/DB01270ApprovedInvestigationalRanibizumab is a recombinant humanized IgG1 kappa isotype monoclonal antibody fragment directed against human vascular endothelial growth factor A (VEGF-A), which is a glycoprotein implicated in the pathophysiology of age-related macular...
Phenobarbital
go.drugbank.com/drugs/DB01174ApprovedInvestigationalA barbituric acid derivative that acts as a nonselective central nervous system depressant. It promotes binding to inhibitory gamma-aminobutyric acid subtype receptors, and modulates chloride currents through receptor channels. It also i...
Mixtures: PB Hyos, Re-PB HyosCategories: P-glycoprotein inducers, P-glycoprotein substratesVerzistobart
go.drugbank.com/drugs/DB18895InvestigationalVerzistobart is under investigation in clinical trial NCT06056895 (Triple Immune Checkpoint Inhibition for Advanced or Metastatic PD-(L)1 Refractory Merkel Cell Carcinoma).